[go: up one dir, main page]

UY31757A1 - Combinación del inhibidor hgf y el inhibidor egf para el tratamiento del cáncer - Google Patents

Combinación del inhibidor hgf y el inhibidor egf para el tratamiento del cáncer

Info

Publication number
UY31757A1
UY31757A1 UY031757A UY31757A UY31757A1 UY 31757 A1 UY31757 A1 UY 31757A1 UY 031757 A UY031757 A UY 031757A UY 31757 A UY31757 A UY 31757A UY 31757 A1 UY31757 A1 UY 31757A1
Authority
UY
Uruguay
Prior art keywords
inhibitor
combination
cancer treatment
hgf
egf
Prior art date
Application number
UY031757A
Other languages
English (en)
Inventor
Lal Bachchu
Laterra John
Kyung Jin Kim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of UY31757A1 publication Critical patent/UY31757A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se dirige hacia un método para tratar cáncer al administrar a un paciente un inhibidro de Factor de Vencimiento de Hepatocito y un inhibidor de, por ejemplo, Factor de Crecimiento Epidérmico.
UY031757A 2008-04-11 2009-04-13 Combinación del inhibidor hgf y el inhibidor egf para el tratamiento del cáncer UY31757A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4444008P 2008-04-11 2008-04-11

Publications (1)

Publication Number Publication Date
UY31757A1 true UY31757A1 (es) 2009-09-30

Family

ID=41152337

Family Applications (1)

Application Number Title Priority Date Filing Date
UY031757A UY31757A1 (es) 2008-04-11 2009-04-13 Combinación del inhibidor hgf y el inhibidor egf para el tratamiento del cáncer

Country Status (7)

Country Link
US (2) US20090258014A1 (es)
AR (1) AR073442A1 (es)
CL (1) CL2009000843A1 (es)
PE (1) PE20091827A1 (es)
TW (1) TW201002346A (es)
UY (1) UY31757A1 (es)
WO (1) WO2009126834A2 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008545753A (ja) * 2005-06-02 2008-12-18 ギャラクシー バイオテック， エルエルシー 抗体で脳腫瘍を処置する方法
US20100113294A1 (en) * 2007-04-16 2010-05-06 Momenta Pharmaceuticals, Inc. Defined glycoprotein products and related methods
WO2010039248A1 (en) * 2008-10-01 2010-04-08 Ludwig Institute For Cancer Research Methods for the treatment of cancer
JP5579699B2 (ja) * 2009-03-27 2014-08-27 クリングルファーマ株式会社 分子標的薬に対する感受性が低下している癌の治療薬および分子標的薬に対する感受性を増強する医薬組成物
WO2010119991A2 (en) 2009-04-17 2010-10-21 Takeda Pharmaceutical Company Limited Novel method of treating cancer
WO2011119948A1 (en) * 2010-03-26 2011-09-29 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
CA2794697A1 (en) 2010-04-07 2011-10-13 Momenta Pharmaceuticals, Inc. High mannose glycans
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
US9170249B2 (en) 2011-03-12 2015-10-27 Momenta Pharmaceuticals, Inc. N-acetylhexosamine-containing N-glycans in glycoprotein products
JP5908972B2 (ja) * 2011-04-07 2016-04-26 アムジエン・インコーポレーテツド 新規な抗原結合タンパク質
WO2013181575A2 (en) 2012-06-01 2013-12-05 Momenta Pharmaceuticals, Inc. Methods related to denosumab
US20150152184A1 (en) * 2012-06-01 2015-06-04 Momenta Pharmaceuticals, Inc. Methods related to panitumumab
US20170275367A1 (en) 2012-11-21 2017-09-28 Janssen Biotech, Inc. Bispecific EGFR/C-Met Antibodies
PL2922872T3 (pl) 2012-11-21 2019-03-29 Janssen Biotech, Inc. Bispecyficzne przeciwciała przeciwko egfr/c-met
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
WO2014149067A1 (en) 2013-03-15 2014-09-25 Momenta Pharmaceuticals, Inc. Methods related to ctla4-fc fusion proteins
US10464996B2 (en) 2013-05-13 2019-11-05 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
IL244623B (en) 2013-10-14 2022-08-01 Janssen Biotech Inc Cysteine engineered fibronectin type iii domain binding molecules
US20160257754A1 (en) 2013-10-16 2016-09-08 Momenta Pharmaceuticals Inc. Sialylated glycoproteins
TW201609805A (zh) 2013-12-23 2016-03-16 美國禮來大藥廠 結合ｅｇｆｒ及ｍｅｔ之多功能抗體
EP3122900A1 (en) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
EP3433615A1 (en) 2016-03-21 2019-01-30 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods for diagnosis and treatment of solar lentigo
SG11201811062XA (en) 2016-06-21 2019-01-30 Janssen Biotech Inc Cysteine engineered fibronectin type iii domain binding molecules
JP7104703B2 (ja) 2016-12-14 2022-07-21 ヤンセン バイオテツク，インコーポレーテツド Ｃｄ８ａ結合フィブロネクチンｉｉｉ型ドメイン
EP3554561B1 (en) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
WO2018111976A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Pd-l1 binding fibronectin type iii domains
CN113993544A (zh) * 2019-07-24 2022-01-28 神州细胞工程有限公司 用于治疗egfr高表达的癌症的多变剂量方法
EP4045061A4 (en) 2019-10-14 2024-04-17 ARO Biotherapeutics Company FIBRONECTIN TYPE III DOMAINS BINDING TO CD137
WO2021076574A2 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
WO2021076543A1 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Epcam binding fibronectin type iii domains
BR112023021318A2 (pt) 2021-04-14 2023-12-19 Aro Biotherapeutics Company Conjugados de domínio fn3-sirna e usos dos mesmos
JP2024517610A (ja) 2021-04-14 2024-04-23 アロ・バイオセラピューティクス・カンパニー Ｃｄ７１に結合するフィブロネクチンｉｉｉ型ドメイン

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943533A (en) * 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US7709454B2 (en) * 1997-06-20 2010-05-04 New York University Methods and compositions for inhibiting tumorigenesis
US7708998B2 (en) * 2000-10-13 2010-05-04 Curis, Inc. Methods of inhibiting unwanted cell proliferation using hedgehog antagonists
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
US7220410B2 (en) * 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
RS53476B (sr) * 2003-07-18 2014-12-31 Amgen Fremont Inc. Sredstva za specifično vezivanje faktora rasta hepatocita
KR20070106029A (ko) * 2005-02-24 2007-10-31 암젠 인코포레이티드 상피세포 성장 인자 수용체 돌연변이
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos

Also Published As

Publication number Publication date
CL2009000843A1 (es) 2009-07-24
US20090258014A1 (en) 2009-10-15
WO2009126834A2 (en) 2009-10-15
PE20091827A1 (es) 2009-11-20
US20120076775A1 (en) 2012-03-29
WO2009126834A3 (en) 2009-12-30
TW201002346A (en) 2010-01-16
AR073442A1 (es) 2010-11-10

Similar Documents

Publication Publication Date Title
UY31757A1 (es) Combinación del inhibidor hgf y el inhibidor egf para el tratamiento del cáncer
UY31756A1 (es) Combinación del inhibidor hgf y el agonista pten para el tratamiento del cáncer
AR061230A1 (es) Prolongacion de la supervivencia de pacientes con cancer con niveles elevados de egf o tgf-alfa
BR112012030699A2 (pt) métodos para tratar câncer de bexiga
NI201000083A (es) Tratamiento de cáncer de mama con un compuesto de 4 - iodo - 3 - nitrobenzamida en combinación con agentes anti-tumorales.
GT200600092A (es) Alargar el tiempo hasta la progresion de la enfermedad o la supervivencia de los pacientes de cancer
BR112014009993A2 (pt) método para o tratamento de tumores do estroma gastrointestinal
GEP20156310B (en) Methods of using c-met modulators
CY1115902T1 (el) Συνδυαστικη θεραπεια καρκινου με ανασταλτικες ενωσεις hps90
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
CO6531463A2 (es) Combinaciones de un inhibidor de pi3k y un inhibidor de mek
MX2015011753A (es) Metodos para tratar cancer de vegija.
UY32480A (es) Derivados de benzofuranilo
NI200700296A (es) Imidazoquinolinas como inhibidores de cinasa de lipido
BR112014031806A8 (pt) método para tratamento de câncer positivo para gd2
NZ628757A (en) Pharmaceutical compositions and methods for treating cancer
CO6390111A2 (es) Productos sanguíneos deshidratados por aspersión y métodos para elaborar los mismos
MX374749B (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tratar cancer.
MX2012005030A (es) Nuevo uso antitumoral de cabazitaxel.
UA107562C2 (uk) Спосіб лікування псоріазу
DOP2012000317A (es) Compuestos heterociclicos, su preparacion y su aplicacion terapeutica
BR112012027393A2 (pt) composto da fórmula geral i, composição farmacêutica, uso de um composto e método de tratamento de qualquer mamífero, notadamente um humano, afetado por câncer
BR112012006070A2 (pt) composições e métodos para tratar distúrbios convulsivos.
CR20110687A (es) Procedimientos de uso del factor liberador de corticotropina para el tratamiento de cancer
WO2011133826A3 (en) Method for treating pancreatic cancer

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181025